Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Glutamine PET Imaging Colorectal Cancer

NCT03275974
completedphase_2

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

NCT03824535
completedphase_2

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

NCT02448225

Clinical Trials (3)

Showing 3 of 3 trials
NCT03275974Phase 1

Glutamine PET Imaging Colorectal Cancer

Terminated
NCT03824535Phase 2

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Completed
NCT02448225Phase 2

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3